Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lupin

Sanofi reception

Sanofi and Boehringer agree asset swap deal

Will exchange Merial animal health business for consumer healthcare unit in $25bn deal

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Boehringer Ingelheim launches ‘gamified’ COPD initiative

Programme aims to encourage and reward disease management

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

- PMLiVE

The human perspective

Boehringer’s HR lead Andreas Neumann on the company’s strategic changes and the role of company culture

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

Boehringer Ingelheim headquarters

Boehringer crowdsources psychiatric research team

Collaboration with BioMed X aims to identify new treatment approaches

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...

Evoke Mind+Matter

Boehringer Ingelheim Professor Andreas Barner

Boehringer Ingelheim returns to growth after US turnaround

But expects only a minor sales increase during a transitional 2016

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links